NASDAQ:NK

NantKwest - NK Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: $4.36
▼
$4.76
50-Day Range: $16.09
▼
$38.70
52-Week Range: $2.52
▼
$45.42

Volume: 1.22 million shs
Average Volume: 1.57 million shs
Market Capitalization: $497.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About NantKwest (NASDAQ:NK) Stock

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Receive NK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NantKwest and its competitors with MarketBeat's FREE daily newsletter.

NK Stock News Headlines

August 12, 2022 | finance.yahoo.com

Global Engineered T Cells Market Report 2022-2027: Immuno-Oncology Sector Increasing R&D Funding & Expanding Gene Therapy Marketspace Generating High-Potential Opportunities - Yahoo Finance

August 11, 2022 | benzinga.com

Global Engineered T Cells Market Report 2022-2027: Increasing Demand for Innovative Biopharmaceutical The - Benzinga

August 17, 2022 | Investing Trends (Ad)

How High Can Copper Go?

To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?

July 6, 2022 | finance.yahoo.com

Harpoon Therapeutics Expands Leadership Team - Yahoo Finance

June 18, 2022 | streetinsider.com

Celldex (CLDX) Appoints Cheryl L. Cohen and Dr. Garry Neil to its Board - StreetInsider.com

June 16, 2022 | finance.yahoo.com

Celldex Announces Two New Appointments to its Board of Directors - Yahoo Finance

May 4, 2022 | finance.yahoo.com

RAPT Therapeutics Expands Leadership Team with Multiple Key Hires - Yahoo Finance

March 29, 2022 | businessinsider.com

List: the 17 Fastest-Growing Biotechs and Pharmas of 2021 - Business Insider

August 17, 2022 | Investing Trends (Ad)

How High Can Copper Go?

March 10, 2022 | businesswire.com

Natural Killer (NK) Cell Therapy Market Research Report 2022 - Comprehensive Insights about 100+ Companies and 185+ Pipeline Drugs - ResearchAndMarkets.com - Business Wire

February 10, 2022 | ft.com

Biotechs face cash crunch after stock market ‘bloodbath’ - Financial Times

January 29, 2022 | businesswire.com

Bladder Cancer Disease Market Analysis Research Report 2021 - ResearchAndMarkets.com - Business Wire

December 20, 2021 | finance.yahoo.com

ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing - Yahoo Finance

October 29, 2021 | businesswire.com

Ambrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update - Business Wire

October 20, 2021 | businesswire.com

Global Natural Killer Cell Therapies Pipeline Insight Report 2021: 100+ Companies and 140+ Pipeline Drugs - ResearchAndMarkets.com - Business Wire

August 18, 2021 | reuters.com

Fed Circ says inventor doesn't owe PTO's expert fees in patent appeal - Reuters

August 13, 2021 | benzinga.com

Analyzing Tattooed Chef's Unusual Options Activity

July 19, 2021 | seekingalpha.com

ImmunityBio: Market Has Lost Contact Following Merger - Seeking Alpha

July 12, 2021 | marketwatch.com

Natural Killer (NK) Cell Therapeutics Market Competitive Research And Precise Outlook 2021 To 2027

July 2, 2021 | streetinsider.com

Ambrx Appoints Sonja Nelson as Chief Financial Officer - StreetInsider.com

July 1, 2021 | streetinsider.com

Ambrx (AMAM) Appoints Sonja Nelson to CFO - StreetInsider.com

July 1, 2021 | businesswire.com

Ambrx Appoints Sonja Nelson as Chief Financial Officer - Business Wire

June 30, 2021 | marketwatch.com

ADRs End Lower; Luckin Coffee, Ambrx Among Companies Actively Trading - MarketWatch

June 23, 2021 | globenewswire.com

Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as - GlobeNewswire

June 14, 2021 | uk.finance.yahoo.com

Global NK Cell Therapies Pipeline Market Report 2021 - ResearchAndMarkets.com

May 21, 2021 | bloomberg.com

Covid-19 Pandemic: Live Updates and News for May. 21, 2021 - Bloomberg

May 13, 2021 | streetinsider.com

CytRx Comments on Quarterly Results and Year-to-Date Progress - StreetInsider.com

See More Headlines

Receive NK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NantKwest and its competitors with MarketBeat's FREE daily newsletter.

NK Company Calendar

Last Earnings: 5/11/2020
Today: 8/17/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NK
CUSIP: N/A
CIK: 1326110
Web: www.nantkwest.com
Phone: 858-633-0300
Fax: N/A
Employees: 160
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-65,790,000.00
Net Margins: -76,658.58%
Pretax Margin: N/A
Return on Equity: -56.06%
Return on Assets: -46.93%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.74
Quick Ratio: 4.74

Sales & Book Value

Annual Sales: $40,000.00
Price / Sales: 12,437.99
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.23 per share
Price / Book: 3.70

Miscellaneous

Outstanding Shares: 109,345,000
Free Float: N/A
Market Cap: $497.52 million
Optionable: Optionable
Beta: 2.61

Key Executives

Dr. Barry J. Simon (Age 56)
Pres, Chief Admin. Officer & Exec. Director
Comp: $454.44k
Ms. Sonja Nelson (Age 48)
Chief Financial Officer
Comp: $442.69k
Mr. Richard Gerald Adcock (Age 52)
Chief Exec. Officer
Mr. Steven Yang J.D.
VP, Gen. Counsel & Corp. Sec.
Dr. Jerel A. Banks Ph.D. (Age 46)
M.D., Sr. VP Mergers and Acquisitions
Mr. Leonard S. Sender
Sr. VP of Medical Affairs - Pediatric, Adolescent & Young Adult Oncology
Dr. Hans Georg Klingemann (Age 71)
VP of R&D

Key Competitors

View All Competitors

NK Stock - Frequently Asked Questions

How were NantKwest's earnings last quarter?: NantKwest, Inc. (NASDAQ:NK) released its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. NantKwest had a negative net margin of 76,658.58% and a negative trailing twelve-month return on equity of 56.06%.
What is Dr. Patrick Soon-Shiong's approval rating as NantKwest's CEO?: 14 employees have rated NantKwest Chief Executive Officer Dr. Patrick Soon-Shiong on Glassdoor.com. Dr. Patrick Soon-Shiong has an approval rating of 55% among the company's employees. This puts Dr. Patrick Soon-Shiong in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of NantKwest own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NantKwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN) and ADMA Biologics (ADMA).
When did NantKwest IPO?: (NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.

What is NantKwest's stock symbol?: NantKwest trades on the NASDAQ under the ticker symbol "NK."
What is NantKwest's stock price today?: One share of NK stock can currently be purchased for approximately $4.55.
How much money does NantKwest make?: NantKwest (NASDAQ:NK) has a market capitalization of $497.52 million and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.
How many employees does NantKwest have?: The company employs 160 workers across the globe.
How can I contact NantKwest?: NantKwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The official website for the company is www.nantkwest.com. The biotechnology company can be reached via phone at 858-633-0300 or via email at investors@nantkwest.com.

This page (NASDAQ:NK) was last updated on 8/17/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

NantKwest - NK Stock Forecast, Price & News

About NantKwest (NASDAQ:NK) Stock

NK Stock News Headlines

NK Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NK Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources